Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 3Neoplasms 2Advanced Solid Neoplasm 2Solid Tumors 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Melanoma 1Lymphoma 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Advanced Solid Tumors 1Advanced Nonhematologic Malignancies 1

Interventions

Paclitaxel 12atezolizumab 11Gemcitabine 9pembrolizumab 8Injections 6Carboplatin 6Irinotecan 5Docetaxel 5Cetuximab 5tocilizumab 4navitoclax 4Leucovorin 4Fluorouracil 4Bevacizumab 4olaparib 3cobimetinib 3Oxaliplatin 3Nivolumab 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2tivozanib 2tislelizumab 2spartalizumab 2ridaforolimus 2plocabulin 2obinutuzumab 2motesanib diphosphate 2liposomal doxorubicin 2linifanib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors × pevonedistat × Clear all
NCT01862328 2020-06-22

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Takeda

Phase 1 Completed
64 enrolled 21 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡